Cargando…

Orexin receptor antagonists as therapeutic agents for insomnia

Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, or non-restorative sleep with impairment of daytime functioning. Currently, treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) and pharmacological therapy. Among pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Equihua, Ana C., De La Herrán-Arita, Alberto K., Drucker-Colin, Rene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872321/ https://www.ncbi.nlm.nih.gov/pubmed/24416019 http://dx.doi.org/10.3389/fphar.2013.00163

Ejemplares similares

Narcolepsy and Orexins: An Example of Progress in Sleep Research
por: De la Herrán-Arita, Alberto K., et al.
Publicado: (2011)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
por: Xue, Tao, et al.
Publicado: (2023)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
por: Merlo Pich, Emilio, et al.
Publicado: (2014)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy
por: Fitch, Thomas E., et al.
Publicado: (2014)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
por: Rocha, Rebeka Bustamante, et al.
Publicado: (2023)

Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
por: Dugovic, Christine, et al.
Publicado: (2014)

The clinical efficacy of orexin antagonists for primary insomnia- A review of the evidence
por: Vasiliu, O.
Publicado: (2023)

Orexin Receptor Competitive Antagonists: A Novel target of the Sedative and hypnotics drugs for the pharmacotherapy of Insomnia
por: Banerjee, Indrajit
Publicado: (2018)

Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review
por: Besterman, Aaron D., et al.
Publicado: (2021)

The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats
por: Morairty, Stephen R., et al.
Publicado: (2014)

Orexin A and orexin receptor 1 axonal traffic in dorsal roots at the CNS/PNS interface
por: Colas, Damien, et al.
Publicado: (2014)

A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
por: Ziemichód, Wojciech, et al.
Publicado: (2022)

The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
por: Steiner, Michel A., et al.
Publicado: (2013)

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
por: Illenberger, Jessica M., et al.
Publicado: (2023)

Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice
por: Etori, Keishi, et al.
Publicado: (2014)

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review
por: Kishi, Taro, et al.
Publicado: (2021)

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators
por: Ramirez, Andres D., et al.
Publicado: (2013)

Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation
por: Bonaventure, Pascal, et al.
Publicado: (2017)

OX(1) and OX(2) orexin/hypocretin receptor pharmacogenetics
por: Thompson, Miles D., et al.
Publicado: (2014)

Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor
por: Pardon, Marie, et al.
Publicado: (2022)

Factors Associated with Prescriptions for an Orexin Receptor Antagonist Among Japanese Patients with Insomnia: Analysis of a Nationwide Japanese Claims Database
por: Okuda, Shoki, et al.
Publicado: (2023)

Hypocretin (orexin) regulation of sleep-to-wake transitions
por: de Lecea, Luis, et al.
Publicado: (2014)

Orexin, cardio-respiratory function, and hypertension
por: Li, Aihua, et al.
Publicado: (2014)

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
por: Connor, Kathryn M., et al.
Publicado: (2016)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Multiomics integration reveals the effect of Orexin A on glioblastoma
por: Yang, Sha, et al.
Publicado: (2023)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
por: Maramai, Samuele, et al.
Publicado: (2016)

Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks
por: Blankenbach, Kira V., et al.
Publicado: (2016)

Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy
por: Kohlmeier, Kristi A., et al.
Publicado: (2013)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists
por: Gozzi, Alessandro, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_28n45gjb6ja44vf11mgf72rb3b